Con­struc­tion kicks off at BeiGene's next US man­u­fac­tur­ing flag­ship

BeiGene is ex­pand­ing its man­u­fac­tur­ing out­side of the US and has made it clear that it’s com­mit­ted to spend­ing “sev­er­al hun­dred mil­lion dol­lars” to do so. And on Fri­day, it broke ground on its new US flag­ship site in Hopewell, NJ.

The new site will open af­ter the first phase of con­struc­tion, which is slat­ed to add 400,000 square-feet of com­mer­cial-stage bi­o­log­ic man­u­fac­tur­ing space, with room for 16,000 liters of ca­pac­i­ty. Con­struc­tion is set to wrap in late 2023 or 2024. Its ex­pan­sion plans have been cen­tered around the blood can­cer drug Brukin­sa, which was ap­proved in 2021 by the FDA to treat a rare form of lym­phoma named Walden­ström’s macroglob­u­line­mia. Just a day be­fore, that drug gained ap­proval in Uruguay in man­tle cell lym­phoma, mar­gin­al zone lym­phoma, and Walden­ström’s macroglob­u­line­mia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER